Skip to main content
    M

    MacroGenics Inc (MGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.31
    -0.11 (-3.22%)

    Market Cap: $217.85M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(17/39)
    Avg Surprise
    -18.76%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.17 - $-0.08
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.31+59.3%
    60d ago$-0.31+59.3%
    30d ago$-0.31+59.3%
    7d ago$-0.27+52.9%
    Current$-0.13
    Revenue Consensus
    $39M
    Range$10M - $62M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.14
    Range$-2.78 - $0.14
    7 analysts
    Revenue Consensus
    $-5365340
    Range$-48160840 - $35M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.14---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 13
    		$-0.27$-0.34+20.59%Beat+52.6%
    Mar 26
    Reported May 13
    		$-0.58$-0.55-5.45%Miss+10.8%
    Dec 25
    Reported Mar 9
    		$-0.22$-0.27+18.40%Beat+73.1%
    Sep 25
    Reported Nov 12
    		$0.27$-0.44+161.36%Beat-70.0%
    Jun 25
    Reported Aug 14
    		$-0.57$0.38-250.00%Miss+36.0%
    Mar 25
    Reported May 13
    		$-0.65$-0.69+5.80%Beat+22.6%
    Dec 24
    Reported Mar 20
    		$-0.82$-0.59-38.64%Miss-9.1%
    Sep 24
    Reported Nov 5
    		$0.90$0.60+50.00%Beat+273.1%
    Jun 24
    Reported Aug 6
    		$-0.89$-0.59-50.85%Miss-27.1%
    Mar 24
    Reported May 9
    		$-0.84$-0.64-31.25%Miss-37.7%
    Dec 23
    Reported Mar 7
    		$-0.75$-0.15-400.00%Miss-457.1%
    Sep 23
    Reported Nov 6
    		$-0.52$-0.35-48.57%Miss-30.0%
    Jun 23
    Reported Aug 9
    		$-0.70$-0.50-40.00%Miss-4.5%
    Mar 23
    Reported May 9
    		$-0.61$0.35-274.29%Miss+43.5%
    Dec 22
    Reported Mar 15
    		$0.21$0.10+110.00%Beat+122.1%
    Sep 22
    Reported Nov 3
    		$-0.40$-0.36-11.11%Miss+53.5%
    Jun 22
    Reported Aug 8
    		$-0.67$-0.97+30.93%Beat-1.5%
    Mar 22
    Reported May 3
    		$-1.08$-0.85-27.06%Miss-20.0%
    Dec 21
    Reported Feb 24
    		$-0.95$-0.81-17.28%Miss-2275.0%
    Sep 21
    Reported Nov 2
    		$-0.86$-0.71-21.13%Miss-30.3%
    Jun 21
    Reported Jul 29
    		$-0.66$-0.41-60.98%Miss+29.8%
    Mar 21
    Reported Apr 29
    		$-0.90$-0.63-42.86%Miss+1.1%
    Dec 20
    Reported Feb 25
    		$-0.04N/A+93.33%Beat+93.5%
    Sep 20
    Reported Nov 4
    		$-0.66$-1.02+35.29%Beat+27.5%
    Jun 20
    Reported Jul 30
    		$-0.94$-1.00+6.00%Beat+10.5%
    Mar 20
    Reported May 5
    		$-0.91$-1.02+10.78%Beat+8.1%
    Dec 19
    Reported Feb 25
    		$-0.62$-1.16+46.55%Beat+41.5%
    Sep 19
    Reported Nov 6
    		$-0.91$-1.11+18.02%Beat-12.3%
    Jun 19
    Reported Jul 31
    		$-1.05$-1.07+1.87%Beat-1.9%
    Mar 19
    Reported May 1
    		$-0.99$-0.87-13.79%Miss+26.1%
    Dec 18
    Reported Feb 26
    		$-1.06$-1.02-3.92%Miss-135.8%
    Sep 18
    Reported Nov 7
    		$-0.81$-1.30+37.69%Beat+36.7%
    Jun 18
    Reported Aug 7
    		$-1.03$-1.21+14.88%Beat+9.6%
    Mar 18
    Reported May 7
    		$-1.34$-1.10-21.82%Miss-24.1%
    Dec 17
    Reported Feb 27
    		$2.96$2.21+33.94%Beat+396.0%
    Sep 17
    Reported Nov 8
    		$-1.28$-1.04-23.08%Miss-
    Jun 17
    Reported Aug 2
    		$-1.14$-1.00-14.00%Miss-
    Mar 17
    Reported May 3
    		$-1.08$-0.91-18.68%Miss-
    Dec 16
    Reported Feb 28
    		$-1.00$-0.89-12.36%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.14EV/EBITDAN/A
    Price/FCF-3.21xFCF Yield-31.14%
    Profitability
    Profit Margin-8.33%Operating Margin-42.20%
    ROE-225.90%ROIC-40.97%
    Financial Health
    Debt/Equity0.70xInterest Coverage-2.24x
    Current Ratio2.96xQuick Ratio2.96x
    Trading Statistics
    Beta1.21Avg Volume625.82K
    52-Week High$5.0852-Week Low$1.29

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.59
    SMA 20$3.77
    SMA 50$3.97
    SMA 200$3.35
    EMA 10$3.59
    EMA 20$3.72
    EMA 50$3.89
    EMA 200$3.42

    MACD

    Line: -0.15Signal: -0.12Hist: -0.03

    ADX

    ADX: 11.3+DI: 15.9-DI: 28.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$3.75

    Bollinger Bands

    Upper Band$4.26
    Lower Band$3.28
    %B Position2578%(Upper)
    Band Width0.03

    RSI (14-Day)

    Neutral
    35.7

    Momentum Oscillators

    Stoch %K20.7
    Stoch %D28.5
    Williams %R-87.0
    ROC (10d)-14.2%
    Momentum-0.55
    CCI (20d)-171.8
    MFI (14d)39.4

    Volatility Measures

    ATR (14d)$0.23(7.0%)
    StdDev (20d)0.24
    Hist Vol70.3%(High)

    Volume Flow

    VWAP$3.31
    OBV56.8M
    AD Line-39.1M
    CMF (20d)0.008

    Volume Metrics

    Avg Vol (20d)659.4K
    Vol Ratio1.4x
    VWMA (20d)$3.77

    Pivot Points

    R3$3.99
    R2$3.86
    R1$3.64
    Pivot Point$3.51
    S1$3.29
    S2$3.16
    S3$2.94

    Advanced Oscillators

    TSI-17.59
    Ultimate Osc44.9
    KST-114.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$32.83M$20.77M$41.23M$72.84M$6.87M$13.19M$19.35M$110.71M$10.80M$9.10M$10.72M$10.40M
    Cost of Revenue$0$0$11.82M$0$0$0$233,000$168,000$176,000$270,000$163,000$85,000
    Gross Profit$32.83M$20.77M$41.23M$72.84M$6.87M$13.19M$19.12M$110.54M$10.62M$8.83M$10.56M$10.31M
    Operating Expenses$46.68M$54.21M$53.32M$54.20M$50.09M$55.82M$71.96M$56.35M$68.80M$62.58M$59.91M$45.81M
    R&D$38.78M$34.97M$33.97M$32.71M$40.79M$39.70M$38.89M$40.54M$51.73M$46.03M$47.35M$30.13M
    SG&A$7.90M$9.71M$9.23M$9.90M$9.30M$10.72M$27.81M$14.10M$14.42M$14.71M$12.56M$12.41M
    Operating Income$-13,852,000$-33,439,000$-12,095,000$18.64M$-43,224,000$-42,624,000$-52,838,000$54.19M$-58,181,000$-53,750,000$-49,354,000$-35,502,000
    Interest Income$-52,762,000$0$0$0$0$0$0$0$0$0$0$50.00M
    Interest Expense$4.40M$4.89M$4.27M$3.34M$802,000$91,000$-24,000$0$6,000$1.13M$0$0
    Income Before Tax$-69,642,000$-38,328,000$-13,253,000$16.82M$-42,612,000$-42,715,000$-11,784,000$56.31M$-55,664,000$-54,883,000$-39,668,000$14.50M
    Income Tax Expense$0$0$0$0$105,000$0$0$0$0$0$0$0
    Net Income$19.52M$-36,774,000$-14,155,000$16.82M$-36,251,000$-41,036,000$-15,421,000$56.31M$-55,664,000$-52,190,000$-46,072,000$17.55M
    EBITDA$-12,221,000$-32,489,000$-11,034,000$21.44M$-40,214,000$-41,035,000$-50,970,000$57.77M$-54,786,000$-53,224,000$-49,182,000$-35,424,000
    EBIT$-12,484,000$-33,439,000$-12,095,000$20.16M$-41,810,000$-42,624,000$-52,838,000$56.31M$-55,658,000$-53,750,000$-49,354,000$-35,502,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MGNX

    Government Contracts

    Gov Obligations (TTM)
    -$549735
    Gov Obligations / Revenue
    -0.3%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Sep 30, 2026.

    News

    MacroGenics doses first patient in MGC030 cancer trial By Investing.com

    MacroGenics Inc. has initiated a Phase 1 study for its new antibody-drug conjugate (ADC), MGC030, with the first patient dosed. This trial targets advanced solid tumors...

    Investing.com Canada•10/15/26•Bullish

    MacroGenics stock has October 23 data ahead in 2026

    MacroGenics (MGNX) is scheduled to present MGC026 data at the ESMO Congress from October 23 to October 27, 2026...

    ad-hoc-news.de•10/15/26•Neutral

    MacroGenics doses first patient in MGC030 cancer trial

    MacroGenics Inc. (NASDAQ:MGNX) has initiated a Phase 1 study for its new antibody-drug conjugate, MGC030, by dosing the first patient. The trial will assess the safety, tolerability, pharmacokinetics, immunogenicity...

    Investing.com•10/15/26•Bullish

    MacroGenics Doses First Patient in MGC030 Phase 1 Study | MGNX Stock News

    MacroGenics (MGNX) has initiated a Phase 1 study for its new antibody-drug conjugate, MGC030, by dosing the first patient with advanced solid tumors. This open-label, multi-center trial aims to evaluate the safety...

    Stock Titan•10/15/26•Bullish

    Form 4 MacroGenics Inc For: 10 October By Investing.com

    This article from Investing.com UK reports on a Form 4 filing for MacroGenics Inc., dated October 10. The filing, which details changes in company ownership, indicates that MacroGenics Inc. experienced a -3.22% change.

    Investing.com UK•10/10/26•Neutral

    MGNX Valuation and Fair Value

    P/E
    -4.1x
    Forward P/E
    61.0x
    P/FCF
    -3.2x
    PEG
    0.0x
    P/B
    4.9x
    See GNG's fair value

    MGNX Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -42.2%
    Net margin
    -8.3%
    ROIC
    -41.0%
    ROE
    -225.9%
    FCF margin
    -39.1%
    FCF yield
    -31.1%

    MGNX Competitors

    CompanyTicker
    Keros Therapeutics IncKROS
    Larimar Therapeutics IncLRMR
    InflaRx N.V.IFRX
    Owens & Minor IncOMI
    Pyxis Oncology IncPYXS
    Protalix Biotherapeutics IncPLX
    SIGA Technologies IncSIGA
    Alector IncALEC

    Sector: Healthcare

    MGNX Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    2
    Hold
    4
    Sell
    0
    Strong Sell
    0

    MGNX Bull Case vs Bear Case

    Bull case

    • MGNX grew quarterly revenue 378.0% year over year.

    Bear case

    • MGNX has a -8.3% net profit margin.

    MGNX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -4.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.13
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About MGNX

    Does MGNX pay dividends?

    MacroGenics Inc (MGNX) does not currently pay a regular dividend.

    What is MGNX's market cap?

    MacroGenics Inc (MGNX) has a market capitalization of $217.85M with a current stock price of $3.31.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In